2022 at a glance
10.0 bn
Invested in research & development
(USD)
(vs. USD 9.5 bn in 2021)
23
Approvals in the US, EU,
for new medicines and new indications for existing medicines
(vs. 21 in 2021)
44
Ongoing Phase III programs
in our development pipeline
(vs. 54 in 2021)
54.6 m
Patients reached
through access programs, predominantly in low- and middle-income countries (LMICs)
(vs. 56.2 m in 2021)
49%
Reduction in greenhouse gas emissions
in our own operations
(vs. 2016 baseline)
98%
Of employees
trained and certified in the Novartis Code of Ethics
(vs. 98% in 2021)
50.5 bn
Net sales
(USD)
(vs. USD 51.6 bn in 2021)
7.5 bn
Dividends
paid to shareholders (USD)
(vs. USD 7.4 bn in 2021)
16.7 bn
Core operating income (USD)
(vs. USD 16.6 bn in 2021)
ESG ratings
Double A list
Novartis was upgraded to A in both CDP Climate Change and CDP Water Security in December.
AA
Novartis was upgraded to AA in the MSCI ESG Ratings assessment in June.
4th
Novartis has ranked in the leadership group for more than 10 years.
16.9
With an ESG Risk Rating score of 16.9, Novartis is assessed as Low Risk.
4th
Novartis ranks fourth in the industry (as of the end of 2022).
